tbuckley/cabot-search huggingface dataset:
EMIC: A Centralized Source of Chemical Mutagenesis Information
Authors: Michael D. Shelby
Journal: Environmental Health Perspectives (1978)

In 1969, a group of scientists concerned with the health hazards posed by environmental mutagens formed the Environmental Mutagen Society to encourage interest in and the study of mutagens in the human environment. In order to deal effectively with this potential health problem, these scientists saw the need for a centralized source of published information on chemicals tested for mutagenicity and, therefore, set down as one of the immediate functions of the Society, the formation of a registry of chemicals tested for mutagenicity. The Environmental Mutagen Information Center (EMIC) was established at Oak Ridge National Laboratory to fill this information need by collecting, organizing, and making available the international literature on chemical mutagenesis. EMIC is now sponsored by the National Institute of Environmental Health Sciences and the National Cancer Institute. From a simple registry of chemicals tested for mutagenicity, the scope and activities of EMIC have increased greatly. EMIC now processes all publications from the open literature dealing with the genetic effects of any environmental agent except those publications dealing exclusively with ultraviolet light or ionizing radiation. Growing concern for the long-term effects of chemical exposure on human health and interest in the relation between mutagenicity and carcinogenicity are placing ever-increasing demands on this Center. As a result of the early realization of the need for literature control, a modern, specialized information center now serves the information needs of mutagenesis workers and other interested persons around the world.
BCL10 gene mutation in lymphoma
Authors: Ming-Qing Du, Huaizheng Peng, Hongxiang Liu, Rifat A. Hamoudi, Tim C. Diss, Tony G. Willis, Hongtao Ye, Ahmet Dogan, Andrew C. Wotherspoon, Martin J. S. Dyer, Peter G. Isaacson
Journal: Blood (2000)
Central bilateral pulmonary infiltrates in an asymptomatic man
Authors: B. F. Corsello
Journal: JAMA (1982)

<h3>History</h3> A 34-year-old asymptomatic man was referred to us for evaluation of an abnormal chest roentgenogram obtained during a preemployment evaluation. He had not suffered from any pulmonary disease in the past, and his family history was unremarkable. No history of drug use or abuse was obtained; he had smoked one pack of cigarettes daily for 15 years. He had done some demolition work in Vietnam from 1965 to 1969, odd jobs in southern California from 1969 to 1979, and less than a year of demolition work in Minnesota just before moving to Wisconsin. He stated that he had had no radiological studies of the chest during the past 12 years. Findings from physical examination, urinalysis, screening blood chemistry studies, and pulmonary function studies (spirometry, lung volumes, diffusing capacity, and arterial blood gases) were normal, as was a complete blood cell count. Posteroanterior (PA) and lateral chest roentgenograms are shown
Epidemic Early Syphilis—Escambia County, Florida, 1987 and July 1989-June 1990
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PMO-177 Maximal boosting of innate immunity during pegylated interferon-α therapy is reached at 48 weeks in e-antigen positive chronic hepatitis B
Authors: U S Gill, M Papadaki, D Peppa, L Micco, L Li, I Ushiro-Lumb, G R Foster, M K Maini, P T F Kennedy
Journal: Gut (2012)

<h3>Introduction</h3> Stopping-rules now exist for Pegylated Interferon-α (PEG-IFNα) treated Chronic Hepatitis B (CHB) patients. Despite the utility of such strategies, the immunological mechanisms that drive HBV DNA and HBsAg decline remain poorly understood. Recent data have identified changes in a subset of NK cells in HBeAg negative disease, which may determine treatment response. However, HBeAg positive disease responds more favourably to PEG-IFNα; here we report on a longitudinal analysis of changes in the immune profile in this cohort, to define the effects of PEG-IFNα on innate immunity. <h3>Methods</h3> PBMCs from a cohort of 17 HBeAg positive patients followed longitudinally at 3 monthly intervals pre, during and post PEG-IFNα therapy were utilised. Phenotypic analysis of NK cells was performed by multicolour flow cytometry. Changes in the immune responses were correlated with simultaneous measurements of ALT, HBV DNA and quantitative HBsAg levels (Abbott ARCHITECT). <h3>Results</h3> PEG-IFNα increased CD56<sup>bright</sup> NK cells by fourfold (mean fold change; MFC 3.7, p=0.0001). This was parallelled by the activation and proliferation of this subset, as marked by HLA-DR and Ki67 expression respectively (MFC 1.5 and 2.3, p=0.009 and p=0.0001 respectively). This increase was more marked at 48 weeks treatment, correlating with a nadir of HBV DNA and HBsAg. The activating (NKG2C and NKp30) and inhibitory (NKG2A) receptors were also analysed in this population. A twofold increase in NKp30 expression (MFC 2.27, p=0.04) was seen which was maximal at 48 weeks, while no significant change was noted for NKG2A and NKG2C. There was a twofold up-regulation of TRAIL expression on CD56<sup>bright</sup> NK cells, which temporally correlated with ALT levels, (MFC 1.8, p=0.0001), this effect was most dramatic at 24 weeks of therapy and sustained to 48 weeks. <h3>Conclusion</h3> PEG-IFNα therapy in this cohort enhances and activates CD56<sup>bright</sup> NK cells. Similarly, TRAIL and NKp30 expression is augmented and sustained throughout treatment and all these effects are maximal at 48 weeks. The restorative innate immune changes begin early and increase throughout therapy in all patients. Thus, 48 weeks therapy may provide the optimal immunological conditions to introduce an oral-antiviral to achieve disease control in PEG-IFNα non-responders. <h3>Competing interests</h3> None declared.
Contribución al estudio de la terapéutica de la infección tuberculosa
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Services
Authors: Hamilton Ballance, Ey Ramsay, Hon Treas, Jamies Smith, Hon Sec, Arthur Jones, Alfred Jones, 2s Djrs, C Joues, E Biddle, H Ward, L Helsby, A Griffiths, Howe Jones, Is Li, Al Drs, E Aw, Abel Roberts, Foster Mo'fft', G Janmes, R Daw- Kin, R Thomas
Journal: BMJ (1922)
Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment*1
Authors: K KOIZUMI
Journal: Hepatology (1995)

Hepatitis C virus (HCV) populations in vivo exist as a mixture of heterogeneous viruses called quasispecies, which have variations in the hypervariable region (HVR). However, the relationship between the diversity of HVR quasispecies, the disease stage, or the interferon (IFN) responsiveness remains to be elucidated. To study these, serum samples were obtained from 42 patients with chronic hepatitis C virus infection; 24 with chronic active hepatitis (CAH) treated with IFN, 9 with cirrhosis, 9 with hepatocellular carcinoma (HCC). HCV quasispecies populations were separated by the single-strand conformation polymorphism (SSCP) method targeted to the HVR. The patients were classified into two groups; a single-band group (n = 12) in which HVR quasispecies was homogeneous and a multiple-band group (n = 30) in which HVR quasispecies was heterogeneous. Patients with multiple bands had significantly more advanced liver disease than those with a single-band group (P = .0082). The percentage of patients with single band were 41% in CAH, 22% in cirrhosis, and 0% in HCC. Multivariate analyses showed that viral diversity was independently related to the progression of liver disease and was not correlated with the duration of infection. We also found that in CAH, the patients who had multiple bands (n = 14) were more resistant to IFN therapy than those who had a single band (n = 10) (P = .002). These results indicate that the diversity of HCV quasispecies becomes more complex as the disease stage progresses and that CAH with more complex diversity shows less IFN effectiveness.
Tuberculous otitis media
Authors: M. K. Jeang
Journal: JAMA (1983)

SINCE the introduction of effective antibiotics, tuberculosis of the middle ear has become a rare entity in the United States and other western countries. Only 11 of 23,000 cases of suppurative otitis media reported from Great Britain during 1950 to 1959 were attributable to<i>Mycobacterium tuberculosis</i>.<sup>1</sup>This represented a substantial change from an early report<sup>2</sup>in which chronic suppurative otitis media was described as being of tuberculous origin in 50% of infants younger than 1 year, 27% of infants younger than 2 years, and 2% of children younger than 15 years. Primarily a disease of children, it has occasionally been reported in adults.<sup>1,3,4</sup> Although it is rare, tuberculous otitis media remains a serious disease. The often painless nature of the infection and low diagnostic suspicion by clinicians serve to delay diagnosis. This may result in severe complications, including deafness, ataxia, cranial nerve palsy, and intracranial abscesses or
Papers and Addresses in Surgery.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Laminated Lung Macrosections: A New Dimension in the Study and Teaching of Pulmonary Pathology
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Squamous NSCLC Improves with Atezolizumab Plus Chemo
Journal: Cancer Discovery (2018)

Abstract A combination of chemotherapy and the PD-L1 inhibitor atezolizumab may be an effective initial therapy for patients with advanced squamous non–small cell lung cancer. In a clinical trial, patients who received the combination had longer progression-free survival, a higher objective response rate, and a longer duration of response than patients who received chemotherapy alone, regardless of PD-L1 expression level.
Therapeutics
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lung Volume Reduction Surgery Puts a New Twist on an Old Technique
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Circulating tumor cells in patients with carcinoma. Method and recent studies
Authors: M. M. Romsdahl
Journal: JAMA (1965)

High-molecular-weight dextran and millipore filtration have been successfully utilized for isolation of cancer cells and large hematopoietic elements from blood. Circulating tumor cells were detected in peripheral blood from nine (3.5%) of 255 patients. Regional blood samples were positive for tumor cells in two of 35 cases. Two of 28 patients having local blood examined were found to have tumor cells. A majority of the patients (11 of 13 cases) with detectable tumor cells in the blood had disseminated cancer. No tumor type predominated in yielding circulating cancer cells. The application of current criteria in the diagnosis of circulating tumor cells indicates that their presence is substantially less than previously reported. Immature hematopoietic elements, which require differentiation from malignant cells, are commonly found in the blood of patients with carcinoma.
THE TOPICAL TREATMENT OF DIPHTHERIA.
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE TRADING-STAMP SYSTEM IN MEDICINE.
Journal: JAMA (1907)

The physician who is looking for dishonest ways of making a living, like the one who is seeking a gold brick, only finds it necessary to glance through his mail to obtain what he covets. In an instance before us, both types are appealed to. The Converse Chemical Company of St. Louis, in a form letter, after calling attention to the fact that "our complete and exact formula is printed on every bottle," goes on to make the following proposition: "If you... will agree to use our preparations where indicated. we will sell you some stock at a price that will be attractive." On further inquiry we find that the company is even more liberal than its letter indicates, for in a later epistle— printed this time—they propose to give the stock away. "For every bottle of either one of our preparations you purchase for $1.00 per bottle delivered to
<i>A Text-Book on Mental Diseases, for the Use of Students and Practitioners of Medicine.</i>By Theodore H. Kellogg, A. M., M. D., late Medical Superintendent of Willard State Hospital, Former Physician-in- Chief of New York City Asylum for the Insane, Former Physician in Charge of Sanford Hall Private Asylum, Former First Assistant Physician of Hudson River State Hospital, and of New York City Asylum. New York: William Wood &amp; Company, 1897
Journal: American Journal of Psychiatry (1897)
Toxic shock syndrome associated with surgical wound infections
Authors: P. Bartlett
Journal: JAMA (1982)

In 13 cases of toxic shock syndrome (TSS) associated with postoperative wound infections, clinical findings were similar to those observed in cases of TSS in menstruating women. While local signs of a surgical wound infection were minimal,<i>Staphylococcus aureus</i>was recovered from cultures of wounds in 12 of 12 patients; multiple blood cultures were negative for 11 of 11 patients. Toxic shock syndrome due to surgical wound infections accompanied a wide variety of surgical procedures in both men and women and was not necessarily associated with menstruation in women. The median interval between surgery and onset of TSS was two days. Toxic shock syndrome can develop in association with surgical wound infections caused by<i>S aureus</i>and should be considered in the differential diagnosis of postoperative fever and hypotension. (<i>JAMA</i>1982;247:1448-1450)
Pathogenesis and Physiopathology of Cystic Fibrosis of the Pancreas
Authors: Paul A. di Sant'Agnese, Richard C. Talamo
Journal: New England Journal of Medicine (1967)

Miscellaneous ObservationsAt the time of writing, several initial observations have been made that are of great potential interest. Spock et al.,168 while studying the effect of serums of patients with cystic fibrosis on human and animal respiratory-tract epithelium in tissue culture, observed that such specimens resulted in an asymmetrical or "jerky" ciliary beats. They studied the ciliary activity by placing a tissue-culture expiant with a ciliary border on a glass slide and exposing the border to serum. An asymmetrical beat was usually observed within ten to fifteen minutes in all cases when serum specimens from 50 patients with cystic . . .
Correction: Monitoring the acute phase response
Journal: BMJ (1989)

delayed the summary being typed and sent for up to six months after patients had been discharged.Such problems are not unique to our hospital.We decided to produce short computerised summaries as close to the time of discharge as practicable using purely medical input.This was achieved with a 16 bit MSDOS computer (RML Nimbus) with a hard disk, using the database